Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 0.55 |
| ▸ | ATR | Q13535 | 15/20 | 0.55 |
| ▸ | ATRIP | Q8WXE1 | 15/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 15/20 | 0.55 |
| ▸ | ATM | Q13315 | 9/20 | 0.55 |
| ▸ | MTOR | P42345 | 6/20 | 0.54 |
| ▸ | SERPINA2 | P20848 | 3/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | NPM1 | P06748 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796636 | 0.91 | PRKDC (0.50) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL20374457 | 0.91 | PRKDC (0.67) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL797021 | 0.82 | PRKDC (0.46) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL797022 | 0.82 | PRKDC (0.46) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL797783 | 0.77 | NPM1 (0.42) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL21541782 | 0.74 | PRKDC (0.82) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL30359504 | 0.74 | PRKDC (0.82) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL29558944 | 0.72 | PRKDC (0.52) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL29688073 | 0.72 | PRKDC (0.47) | PRKDCATRATRIPPIK3CBATM | |
| SCHEMBL20374536 | 0.72 | PRKDC (0.52) | PRKDCATRATRIPPIK3CBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| EP-2616468-A1 | FUSED HETEROARYLS AND THEIR USES | Hutchison Medipharma Limited (CN) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | PRKDC 3135/4885ATR 3548/4885ATRIP 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.